PHA-739358 for the Treatment of Multiple Myeloma

• Status: Terminated
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the antitumor activity of PHA-739358 as single agent IV infusion in adult patients with Multiple Myeloma who have a history of at least 2 previous lines of treatment for the disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nerviano Medical Sciences

Criteria

Inclusion Criteria:

• active multiple myeloma progressing after at least 2 prior lines of treatment

• measurable disease

• t(4;14) translocation

• life expectancy of at least 3 months

Exclusion Criteria:

• uncontrolled hypertension

• myocardial infarction, unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the past 6 months.

• pregnancy or breast feeding

• active infections, including HIV